Vecuronium Bromide Injection, Powder, For Solution
NDC Package 0143-9232-10
Package Information
Vecuronium Bromide injection is vecuronium bromide is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. This formulation utilizes a injection, powder, for solution delivery system. Marketed by Hikma Pharmaceuticals Usa Inc., this product is identified by NDC 0143-9232 and is authorized under FDA application ANDA203725.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0143 - Hikma Pharmaceuticals Usa Inc.
- 0143-9232 - Vecuronium Bromide
- 0143-9232-10 - 10 VIAL in 1 CARTON / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL (0143-9232-01)
- 0143-9232 - Vecuronium Bromide
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0143-9232-10 identifies a specific commercial package of 10 vial in 1 carton / 1 injection, powder, for solution in 1 vial (0143-9232-01) of Vecuronium Bromide, a human prescription drug labeled by Hikma Pharmaceuticals Usa Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 10 billable units per package. This injection, powder, for solution is formulated for intravenous use and contains vecuronium bromide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hikma Pharmaceuticals Usa Inc. on August 01, 2019. The current certification is valid through December 31, 2027.
How is this Hikma Pharmaceuticals Usa Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00143923210. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 10 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.